top of page

Corporate Announcements

All Posts

Gamma Life Announces the Debut of LIFER II, a 40Hz Based Digital, AI Driven Wearable Device. An IIT Phase I Trial is Planned for Early Parkinson's Treatment

Gamma Life Announces the Debut of LIFER II, a 40Hz Based Digital, AI Driven Wearable Device. An IIT Phase I Trial is Planned for Early Parkinson's Treatment

Gamma Life Announces the Debut of LIFER II, a 40Hz Based Digital, AI Driven Wearable Device. An IIT Phase I Trial is Planned for Early Parkinson's Treatment

Brick L

Jun 10 min read

NK Life Announces Potent Anti-Tumor Animal Data for DKure at ASCO 2025, with IIT Phase I Planned for the Treatment of HCC,

NK Life Announces Potent Anti-Tumor Animal Data for DKure at ASCO 2025, with IIT Phase I Planned for the Treatment of HCC,

NK Life Announces Potent Anti-Tumor Animal Data for DKure at ASCO 2025, with IIT Phase I Planned for the Treatment of HCC,

Brick L

Jun 10 min read

NK Life Science Investor Meeting Dec 12th, Sunday 2pm

NK Life Science Investor Meeting Dec 12th, Sunday 2pm

NK Life Science Investor Meeting Dec 12th, Sunday 2pm

Create a blog post subtitle that summarizes your post in a few short, punchy sentences and entices your audience to continue reading....

Brick L

Nov 28, 20211 min read

NK Life Science Announces Scientific Advisors

NK Life Science Announces Scientific Advisors

NK Life Science Announces Scientific Advisors

NK LIFE Science proudly announces the formation of its Scientific Advisory Committee Chairperson: Dr. Victor (Shengkan) Jin, Professor of...

Brick L

Nov 28, 20211 min read

NK Life Science Seed Fund Complete

NK Life Science Seed Fund Complete

NK Life Science Seed Fund Complete

Brick L

Nov 28, 20210 min read

LIFE

OFFICE:

315 W 57th St

New York, NY 10019

United States

Tel: 646-470-6066

IR@nklifescience.com

RESEARCH:

303A College Road East

Princeton, NJ 08540

United States

Tel: 609-375-8253

Sign up to Receive News
and Information

Email

Thanks for submitting!

Join Us on the Journey

© 2025 by LIFE Science Corp.

bottom of page